Association between Usage of Prophylactic AYUSH Medicines and Disease Severity in COVID-19 Patients: A Retrospective Cohort Study
Authors: Chaudhary Anupriya , Nayak Debadatta , Pandey Swati , Shastri Vipul , Kamble Madhuri , Pendse Vidya , Prajapati Vismay , Vaidya Brijesh , Rohit Heenal , Beedmani Swaroopa , Presswala Nutan , Patole Tejaswini , Bawaskar Ramesh , Shinde Vaishali , Datta Mohua , Rai Gunjan , Prusty Umakanta , Pal Partha Pratim , Goli Siva Prasad , Sahoo Amulya Ratna , Muraleedharan K. C. , Prakash Pooja , Mahajan Ashish , Singh Anuradha , Krishnan Reetha , Pawaskar Navin , Srivastava Amit , Ningthoujam Gouri Devi , Sadarla Ravi Kumar , Sonny Ranjit , Karso Liyi , Sarkar Subhamoy , Prasad Sunil , Shrivastava Ashish Kumar , Kumar Avinash , Kumar Nitesh , Raveendar Ch. , Kumar BSJ Raja , Sastry VSPK , Dasari Asha , Sundeep K. Samson , Kaushik Subhash , Rath Padmalaya , Gautam Shweta , Shil Ratan Chandra , Swain Trupti Laxmi , Reddy G. Ravi Chandra , Pradeep S. , Stevenson S. , Choubey Gurudev , Debata Lipipushpa , Khurana Anil 
Published: May 2024

Abstract
Background Prior vaccination is often studied for its impact on individuals' post-infection prognosis. Ayurveda, Yoga, Unani, Siddha and Homeopathy (AYUSH) medicines, advised by the Government of India as prophylaxis during the first wave of the coronavirus disease 2019 (COVID-19) pandemic, were consumed by the masses in 2020. A study was therefore undertaken to observe any association between the prior usage of AYUSH prophylactic medicines and post-infection severity as reported by recovered COVID-19 individuals.
Methods This was a retrospective, multi-centre, cohort study conducted in 21 cities of India from 5th August to 30th November 2020. Data from recovered COVID-19 patients, of either sex or any age, captured information about AYUSH prophylactic medicines intake prior to infection, disease severity, symptomatology, duration of complaints, etc. The study participants were grouped into AYUSH intake and non-intake. Primary composite outcome was the disease clinical course. Secondary clinical outcomes were the rate of and time to clinical recovery.
Results Data of 5,023 persons were analysed. Ayurveda or homeopathic prophylactic medicines were consumed by more than half of the study participants: that is, 56.85% (n = 1,556) and 56.81% (n = 1,555) respectively. The overall adjusted protective effect (PE) of AYUSH prophylactic intake against moderate/severe forms of COVID-19 disease was 56.7% (95% confidence interval [CI], 48.7 to 63.50; p < 0.001). Adjusted PE for homeopathy and Siddha was 52.9% (95% CI, 42.30 to 61.50; p < 0.001) and 59.8% (95% CI, 37.80 to 74.10; p < 0.001), respectively. A statistically significant association was found between AYUSH prophylactic medicine intake and clinical recovery more frequently by the 3rd day of illness (χ2 = 9.01; p = 0.002). Time to resolution of symptoms in the AYUSH intake group was on average 0.3 days earlier than in the non-intake group (p = 0.002).
Conclusion AYUSH prophylactics were associated with statistically significant levels of protection against COVID-19 disease severity. Amongst these, previous intake of homeopathy or Siddha medicines was associated with some protection against moderate/severe illness and with a somewhat quicker clinical recovery. Prospective studies with experimental research design are needed to validate the findings of this study.
Study registration Clinical Trials Registry—India (CTRI/2020/08/027000).